Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO

Bibliographic Details
Main Authors: Molina, Jean-Michel, Clotet, Bonaventura, van Lunzen, Jan, Lazzarin, Adriano, Cavassini, Matthias, Henry, Keith, Kulagin, Valeriv, Givens, Naomi, Brennan, Clare, de Oliveira, Carlos Fernando
Format: Online
Language:English
Published: International AIDS Society 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224885/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224885/

Similar Items